HEPATITIS C VIRUS TESTING, LIVER DISEASE ASSESSMENT AND TREATMENT UPTAKE AMONG PEOPLE WHO INJECT DRUGS PRE- AND POST-UNIVERSAL ACCESS TO DIRECT-ACTING ANTIVIRAL TREATMENT IN AUSTRALIA: THE LIVERLIFE STUDY

Bajis S1, Grebely J1, Hajarizadeh B1, Applegate T1, Marshall AD1,2, Harrod ME3, Byrne J4, Dunlop A5, Bath N6, Read P7, Jauncey M8, Collie P8, Edwards M9, Gorton C10, Ezard N11, Hayllar J12, Cock V13, Peterson S14, Thomson C15, Weltman M16, Haber P17, Lam T18, Martinello M1, Maher L1,19 and Dore GJ1 on behalf of the LiveRLife Study Group

1The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia; 2Centre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, Australia; 3NSW Users and AIDS Association, Sydney, New South Wales, Australia; 4Australian Injecting and Illicit Drug Users League, Canberra, ACT, Australia; 5Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, NSW, Australia; 6NSW Users and AIDS Association, NSW, Australia; 7Kirketon Road Centre, Sydney, New South Wales, Australia; 8Coffs Harbour Drug and Alcohol Service, NSW, Australia; 9Campbelltown Drug Health Services, Sydney, NSW, Australia; 10Cairns Sexual Health Service, Cairns, Queensland, Australia; 11Alcohol and Drug Service, St Vincent's Hospital, Sydney, New South Wales, Australia; 12Alcohol and Drug Service, Metro North Mental Health, Metro North Hospital and Health Service, Brisbane, Queensland, Australia; 13Drug and Alcohol Services of South Australia, Adelaide, South Australia, Australia; 14Orange Aboriginal Medical Service, Orange, NSW, Australia; 15Bayside Alcohol and Drug Services, Cleveland, QLD, Australia; 16Gateway Clinic Nepean Hospital, Sydney, NSW, Australia; 17Royal Prince Alfred Hospital, Sydney, NSW, Australia; 18Western Sydney Drug Health Fleet Street Opioid Treatment Medical Services, Sydney, NSW, Australia; 19Burnet Institute, Melbourne, Victoria, Australia.

Background: Gaps in hepatitis C virus (HCV) testing and diagnosis, liver disease assessment and treatment uptake among people who inject drugs (PWID) persist. We aimed to describe the cascade of HCV care among PWID in Australia, prior to and following unrestricted access to direct-acting antiviral (DAA) treatment uptake.

Methods: Participants enrolled in an observational cohort study during liver health campaign days between 2014 and 2018 provided finger-stick whole-blood samples for dried blood spot and Xpert® HCV Viral Load, and venepuncture samples. Participants received transient elastography and clinical assessment by a nurse or general practitioner. Clinical follow-up was recommended 2-12 weeks after enrolment.

Results: Among 839 participants (mean age 43 years), 66% were male (n=550), 64% (n=537) injected drugs in the previous month, and 67% (n=560) reported currently receiving opioid substitution therapy. Overall, 45% (n=380) had detectable HCV RNA, of whom 23% (n=86) received HCV treatment within 12 months of enrolment. HCV treatment uptake increased from 2% in pre-DAA era to 38% in DAA era. Significant liver fibrosis (F2–F4) was more common in participants with HCV infection (38%) than those without (19%). Older age (≥ 51 years group: aOR, 3.17; 95% CI, 1.87–5.34), BMI ≥30 (aOR, 2.51; 95% CI, 1.66–3.81) and detectable HCV
RNA (aOR, 2.79; 95% CI, 1.95–3.99) were associated with significant fibrosis. Age 50 years or older (aOR, 2.88; 95% CI, 1.18–7.04) and attending a clinical follow-up with nurse (aOR, 3.19; 95% CI, 1.61–6.32) or physician (aOR, 11.83; 95% CI, 4.89–28.59) were associated with HCV treatment uptake.

**Conclusion:** HCV treatment uptake among PWID in Australia has increased markedly in the DAA era. Innovative models of care that address the social and structural determinants of access to care are required to further enhance treatment uptake.

**Disclosure of interest Statement:** The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. SB is supported by an Australian Postgraduate Award from UNSW Sydney. JG is supported by a NHMRC Career Development Fellowship. LM is supported by a NHMRC Senior Research Fellowship. GJD is supported by a NHMRC Practitioner Research Fellowship. GD is a consultant/advisor and has received research grants from Abbvie, Gilead and Merck. JG is a consultant/advisor and has received research grants from Abbvie, Cepheid, Gilead Sciences and Merck/MSD.